These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 8349150

  • 1. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Rubin S, Lewis JL, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W.
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [Abstract] [Full Text] [Related]

  • 2. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
    Markman M.
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):17-9; quiz 20, 58. PubMed ID: 8202717
    [Abstract] [Full Text] [Related]

  • 3. Current status of intraperitoneal therapy for ovarian cancer.
    Markman M.
    Curr Opin Obstet Gynecol; 1993 Feb; 5(1):99-104. PubMed ID: 7678757
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS.
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [Abstract] [Full Text] [Related]

  • 5. Gynecological malignancies.
    Schaebler DL, Schilder RJ, Young RC.
    Cancer Chemother Biol Response Modif; 1996 Dec; 16():564-91. PubMed ID: 8639401
    [Abstract] [Full Text] [Related]

  • 6. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H.
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M, Blessing JA, Major F, Manetta A.
    Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
    [Abstract] [Full Text] [Related]

  • 9. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
    Markman M.
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):79-82. PubMed ID: 2669140
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC.
    Cancer Res; 1990 Apr 15; 50(8):2256-60. PubMed ID: 2180564
    [Abstract] [Full Text] [Related]

  • 18. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
    Markman M.
    Cancer J; 2009 Apr 15; 15(2):105-9. PubMed ID: 19390303
    [Abstract] [Full Text] [Related]

  • 19. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Meisner BC, Armstrong DK, Frick KD.
    Gynecol Oncol; 2007 Sep 15; 106(3):476-81. PubMed ID: 17688927
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.
    Gynecol Oncol; 1999 Apr 15; 73(1):96-101. PubMed ID: 10094887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.